ArticleNature biomedical engineering2026
Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.
Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.Human vaccines & immunotherapeutics · 2026Article
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- Advancing In Vivo Chimeric Antigen Receptor T-Cell Engineering to Accelerate Clinical Translation.MedComm · 2026Review
- Microbial Signals in Cancer: Dissecting Host-Microbiota-Tumor Interactions and Potential Therapeutic Strategy.MedComm · 2026Review
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- Multifunctional biohybrid nanoplatform interferes electron transport chain amplifying mitochondrial metabolism-mediated anti-tumor therapy.Materials today. Bio · 2026Article
- Light-driven thermotropic hydrogel with nanomodulator enables lipid intervention and cavity delivery for postsurgical tumor therapy.Cell reports. Medicine · 2026Article
- Advances in delivery technologies-powered cancer vaccines.Bioactive materials · 2026Review
- PD-L1-targeted OMV priming licenses myeloid co-stimulation and chemokine circuits to potentiate CAR-T therapy in advanced-stage solid tumors.Journal of nanobiotechnology · 2026Article
- Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.Nature biomedical engineering · 2026Article
- FomA-Containing Outer Membrane Vesicles of Fusobacterium Nucleatum Facilitate Bladder Cancer Lymphatic Metastasis via IL-6-Dependent M2b Macrophage Polarization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bacterial Membrane Vesicles: Biogenesis, Functions, and Emerging Biotechnological Applications.Microorganisms · 2026Review
- Engineered nanovesicles as a DC vaccine to enhance the antitumor efficacy of CAR-T cells against solid tumors.Journal of nanobiotechnology · 2026Article
- Bacterial extracellular vesicles as central mediators of microbiota-host communication.Frontiers in microbiology · 2026Review
- Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients.Frontiers in oncology · 2026Article
- Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Major challenges facing chimeric antigen receptor (CAR)-T cell therapy for solid tumours include the immunosuppressive tumour microenvironment and the heterogeneity of antigen expression. Bacterial outer membrane vesicles (OMVs) naturally activate the immune system and can be engineered for drug delivery. Here we develop a bacterial OMV-based immunosuppression reversal and optimized antigen decoration platform for CAR-T therapy (BROAD-CAR), in which OMVs are modified to express a high-affinity anti-PD-L1 antibody and load plasmids encoding the target antigen for CARs. By blocking the PD-1/PD-L1 signalling pathway, our tumour-targeting platform enhances the antitumour activity of CAR-T cells both in vitro and in vivo and boosts CAR-T cell expansion by ameliorating the tumour microenvironment. BROAD-CAR also facilitates the in situ antigenic modification of solid tumours and achieves CAR-mediated lysis of antigen-heterogeneous and antigen-negative tumours, inhibiting tumour recurrence and metastasis in the breast cancer mouse models. Our findings highlight a safe and efficient approach to enhance the efficacy and applicability of CAR-T therapy in solid tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.